Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature

Bibliography

• Nilius B, Voets T. TRP channels: a TR(I)P through a world of multifunctional cation channels. Pfluegers Arch 2005;451:1-10
   PubMed Web of Science ®Google Scholar
• Bandell M, Macpherson LJ, Patapoutian A. From chills to chilis: mechanisms for thermosensation and chemesthesis via thermoTRPs. Curr Opin Neurobiol 2007;17:490-7
   PubMedGoogle Scholar
• Caterina MJ. Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol 2007;292:R64-76
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Schumacher MA, Tominaga M, The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24
   PubMed Web of Science ®Google Scholar
• Szallasi A, Cortright DN, Blum CA, The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007;6:357-72
   PubMed Web of Science ®Google Scholar
• Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007;114:13-33
   PubMed Web of Science ®Google Scholar
• Carlton SM, Du J, Zhou S. Group II metabotropic glutamate receptor activation on peripheral nociceptors modulates TRPV1 function. Brain Res 2009;1248:86-95
   PubMedGoogle Scholar
• Jin YH, Yamaki F, Takemura M, Capsaicin-induced glutamate release is implicated in nociceptive processing through activation of ionotropic glutamate receptors and group I metabotropic glutamate receptor in primary afferent fibers. J Pharmacol Sci 2009;109:233-41
   Google Scholar
• Wang H, Kohno T, Amaya F, Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci 2005;25:7986-92
   PubMed Web of Science ®Google Scholar
• Li D, Ren Y, Xu X, Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related peptide driven by dorsal root reflexes. J Pain 2008;9:1155-68
   PubMed Web of Science ®Google Scholar
• Sculptoreanu A, Aura Kullmann F, de Groat WC. Neurokinin 2 receptor-mediated activation of protein kinase C modulates capsaicin responses in DRG neurons from adult rats. J Neurosci 2008;27:3171-81
   Google Scholar
• Ma W, Quirion R. Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain. Expert Opin Ther Targets 2007;11:307-20
   PubMed Web of Science ®Google Scholar
• McGaraughty S, Chu KL, Bitner RS, Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol 2003;90:2702-10
   PubMed Web of Science ®Google Scholar
• Toth A, Boczan J, Kedei N, Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Mol Brain Res 2005;135:162-8
   PubMedGoogle Scholar
• Cristino L, de Petrocellis L, Pryce G, Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006;139:1405-15
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Leffler A, Malmberg AB, Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000;288:306-13
   PubMed Web of Science ®Google Scholar
• Davis JB, Gray J, Gunthorpe MJ, Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000;405:183-7
   PubMed Web of Science ®Google Scholar
• Broad LM, Mogg AJ, Beattie RE, TRP channels as emerging targets for pain therapeutics. Expert Opin Ther Targets 2009;13:69-81
   PubMed Web of Science ®Google Scholar
• Ghilardi JR, Rohrich H, Lindsay TH, Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005;25:3126-31
   PubMed Web of Science ®Google Scholar
• Pomonis JD, Harrison JE, Mark L, N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;306:387-93
   PubMed Web of Science ®Google Scholar
• Honore P, Wismer CT, Mikusa J, A-425619 [1-isoquinolin-5-yl-3-(4-trifl uoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005;314:410-21
   PubMed Web of Science ®Google Scholar
• Gavva NR, Tamir R, Qu Y, AMG9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005;313:474-84
   PubMed Web of Science ®Google Scholar
• Cui M, Honore P, Zhong C, TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006;26:9385-93
   PubMed Web of Science ®Google Scholar
• Pogatzki-Zahn EM, Shimizu I, Caterina M, Heat hyperalgesia after incision requires TRPV1 and is distinct from pure inflammatory pain. Pain 2005;115:296-307
   PubMedGoogle Scholar
• Christoph T, Gillen C, Mika J, Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem Int 2007;50:281-90
   PubMed Web of Science ®Google Scholar
• Gunthorpe, MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 2008;14:32-41
   PubMed Web of Science ®Google Scholar
• Gavva NR, Bannon AW, Hovland DN Jr, Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007;323:128-37
   PubMed Web of Science ®Google Scholar
• Gavva NR, Treanor JJ, Garami A, Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008;136:202-10
   PubMed Web of Science ®Google Scholar
• Gavva NR. Setbacks in the clinical development of TRPV1 antagonists: what next? Open Drug Discov J 2009;1;1-35
   Google Scholar
• Gavva NR, Bannon AW, Surapaneni S, The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 2007;27:3366-74
   PubMed Web of Science ®Google Scholar
• Steiner AA, Turek VF, Almeida MC, Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J Neurosci 2007;27:7459-68
   PubMed Web of Science ®Google Scholar
• Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today 2009;14:56-67
   PubMed Web of Science ®Google Scholar
• Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med 2009;15:14-22
   PubMed Web of Science ®Google Scholar
• Rami HK, Thompson M, Stemp G, Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006;16:3287-91
   PubMed Web of Science ®Google Scholar
• Chizh BA, O'Donnell MB, Napolitano A, The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007;132:132-41
   PubMed Web of Science ®Google Scholar
• Eid S. TRPV1 antagonists: are they too hot to handle? 3rd Annual Pain Therapeutics Summit; 2009
   Google Scholar
• Lehto SG, Tamir R, Deng H, Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(tri fluoromethyl)phenyl)-acrylamide(AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008;326:218-29
   PubMed Web of Science ®Google Scholar
• Broad LM, Keding SJ, Blanco MJ. Recent progress in the development of selective TRPV1 antagonists for pain. Curr Top Med Chem 2008;8:1431-41
   PubMedGoogle Scholar
• Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. BiochemPharmacol 2009;7:211-6
   Google Scholar
• Gharat LA, Szallasi A. TRPV1 antagonists: a survey of the patent literature. Expert Opin Ther Patents 2008;18:159-209
   Web of Science ®Google Scholar
• Kyle DJ, Tafesse L. TRPV1 antagonists: a survey of the patent literature. Expert Opin Ther Patents 2006;16:977-96
   Web of Science ®Google Scholar
• Correll CC, Palani A. Advances in the development of TRPV1 antagonists. Expert Opin Ther Patents 2006;16:783-95
   Web of Science ®Google Scholar
• Sanofi-Aventis. WO2009112679; 2009
   Google Scholar
• Sanofi-Aventis. WO2009112678; 2009
   Google Scholar
• Sanofi-Aventis. WO2009112677; 2009
   Google Scholar
• Sanofi-Aventis. WO2009109710; 2009
   Google Scholar
• Sanofi-Aventis. FR2926554; 2009
   Google Scholar
• Sanofi-Aventis. FR2926553; 2009
   Google Scholar
• Sanofi-Aventis. FR2926555; 2009
   Google Scholar
• Sanofi-Aventis. FR2926556; 2009
   Google Scholar
• Sanofi-Aventis. WO2009050348; 2009
   Google Scholar
• Sanofi-Aventis. FR2919610; 2009
   Google Scholar
• Sanofi-Aventis. WO2008107543; 2008
   Google Scholar
• Sanofi-Aventis. WO2008107544; 2008
   Google Scholar
• Sanofi-Aventis. WO2008093024; 2008
   Google Scholar
• Sanofi-Aventis. FR2911605; 2008
   Google Scholar
• Sanofi-Aventis. FR2911604; 2008
   Google Scholar
• Sanofi-Aventis. FR2910473; 2008
   Google Scholar
• Sanofi-Aventis. FR2904316; 2008
   Google Scholar
• Sanofi-Aventis. FR2903985; 2008
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2007042906; 2007
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2008110863; 2008
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2008059339; 2008
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2009095726; 2009
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2009010824; 2009
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2009081219; 2009
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2009081222; 2009
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2008010061; 2008
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2009090548; 2009
   Google Scholar
• Glenmark Pharmaceuticals S.A. WO2009034433; 2009
   Google Scholar
• Abbott Laboratories. US20060128689; 2006
   Google Scholar
• Abbott Laboratories. WO2008024945; 2008
   Google Scholar
• Abbott Laboratories. WO2009117626; 2009
   Google Scholar
• Abbott Laboratories. US20080287676; 2008
   Google Scholar
• Abbott Laboratories. US20080153871; 2008
   Google Scholar
• Abbott Laboratories. WO2009023539; 2009
   Google Scholar
• Abbott Laboratories. US20090124671; 2009, WO2009055629; 2009
   Google Scholar
• Abbott Laboratories. US20090124666; 2009, WO2009055749; 2009
   Google Scholar
• Gruenenthal GmbH. WO2007045462; 2007
   Google Scholar
• Gruenenthal GmbH. WO2008125295; 2008
   Google Scholar
• Gruenenthal GmbH. DE102007017884; 2008, WO2008125296; 2008
   Google Scholar
• Gruenenthal GmbH. DE102007018151; 2008, WO2008125337; 2008
   Google Scholar
• Gruenenthal GmbH. DE102007018149; 2008, WO2008125342; 2008
   Google Scholar
• Gruenenthal GmbH. WO2008046647; 2008
   Google Scholar
• Pfizer, Inc. WO2008007211; 2008, WO2008090434; 2008
   Google Scholar
• Pfizer, Inc. WO2008032204; 2008
   Google Scholar
• Pfizer, Inc. WO2008050199; 2008
   Google Scholar
• Pfizer, Inc. WO2008059370; 2008
   Google Scholar
• Renovis, Inc. WO2009064449; 2009
   Google Scholar
• Revovis, Inc. WO2009089057; 2009
   Google Scholar
• Pharmeste S.r.l. WO2008075150; 2008
   Google Scholar
• Pharmeste S.r.l. EP1939173; 2008
   Google Scholar
• Pharmeste S.r.l. WO2008006481; 2008
   Google Scholar
• Pharmeste S.r.l. WO2008006480; 2008
   Google Scholar
• Pharmeste Srl. EP2048133; 2009, WO2009043582; 2009
   Google Scholar
• Janssen Pharmaceutica NV. US20080004253; 2008
   Google Scholar
• Janssen Pharmaceutica NV. US20090156598; 2009
   Google Scholar
• Janssen Pharmaceutica NV. US20090156599; 2009
   Google Scholar
• Janssen Pharmaceutica NV. US20080146637; 2008
   Google Scholar
• Neurogen Corp. WO2008024433; 2008
   Google Scholar
• Neurogen Corp. WO2008024438; 2008
   Google Scholar
• Neurogen Corp. WO2008066664; 2008, WO2009121036; 2009
   Google Scholar
• Neurogen Corp. WO2008156607; 2008
   Google Scholar
• Neurogen Corp. WO2009100403; 2009
   Google Scholar
• Purdue Pharma LP. WO2008132600; 2008
   Google Scholar
• Purdue Pharma LP. WO2008133973; 2008
   Google Scholar
• Daewoong Pharmaceutical Co., Ltd. WO2008007900; 2008
   Google Scholar
• Daewoong Pharmaceutical Co., Ltd. WO2009128661; 2009
   Google Scholar
• Schering Corp. WO2008033464; 2008, WO2008033431; 2008
   Google Scholar
• Mochida Pharmaceutical Co., Ltd. WO2008091021; 2008
   Google Scholar
• Amorepacific Corp. WO2009096701; 2009
   Google Scholar
• Amorepacific Corp. WO2009096701; 2009, WO2008013414; 2008
   Google Scholar
• AstraZeneca AB. WO2008018827; 2008
   Google Scholar
• Santen Pharmaceutical Co., Ltd. WO2009051151; 2009
   Google Scholar
• NV Organon. WO2009016241; 2009
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. US20090203667; 2009, WO2008007780; 2008
   Google Scholar
• Nippon Suisan Kaisha, Ltd. WO2008096755; 2008
   Google Scholar
• Phytopharm PLC. WO2008003978; 2008
   Google Scholar
• The Board of Regents of the University of Texas System. WO2008127647; 2008
   Google Scholar
• Redpoint Bio Corporation. WO2008057300; 2008
   Google Scholar
• Alcon Research, Ltd. US2009131449; 2009
   Google Scholar
• The Board of Regents of the University of Texas System. WO2008127603; 2008
   Google Scholar
• Unilever PLC. WO2008046788; 2008
   Google Scholar
• Marsch R, Foeller E, Rammes G, Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007;27:832-9
   PubMed Web of Science ®Google Scholar
• Tzavara ET, Li DL, Moutsimilli L, Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psych 2006;59:508-15
   PubMedGoogle Scholar
• Suri A, Szallasi, A. The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol Sci 2008;29:29-36
   PubMed Web of Science ®Google Scholar
• Honore P, Chandran P, Hernandez G, Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009;142:27-35
   PubMed Web of Science ®Google Scholar
• Alawi K, Keeble J. The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther 2010;125:181-95
   PubMed Web of Science ®Google Scholar